Misplaced Pages

Luvadaxistat

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Luvadaxistat
Clinical data
Other namesNBI-1065844; NBI1065844; TAK-831; TAK831
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • 6-ethyl]-1,2-dihydropyridazine-3,4-dione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC13H11F3N2O2
Molar mass284.238 g·mol
3D model (JSmol)
SMILES
  • C1=CC(=CC=C1CCC2=CC(=O)C(=O)NN2)C(F)(F)F
InChI
  • InChI=1S/C13H11F3N2O2/c14-13(15,16)9-4-1-8(2-5-9)3-6-10-7-11(19)12(20)18-17-10/h1-2,4-5,7H,3,6H2,(H,17,19)(H,18,20)
  • Key:QBQMUMMSYHUDFM-UHFFFAOYSA-N

Luvadaxistat (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; NBI-1065844, TAK-831) is an experimental drug that works as a D-amino acid oxidase (DAAO) inhibitor and is supposed to increase NMDA receptor functionality. It is developed to treat Friedrich ataxia and negative symptoms of schizophrenia. As of September 2024, it is in phase 2 clinical trials for schizophrenia, no recent development has been reported for ataxia, and the drug has been discontinued for Friedreich's ataxia.

References

  1. O’Donnell, Patricio; Dong, Cheng; Murthy, Venkatesha; Asgharnejad, Mahnaz; Du, Xiaoming; Summerfelt, Ann; Lu, Hong; Xu, Lin; Wendland, Jens R.; Dunayevich, Eduardo; Buhl, Derek L.; Litman, Robert; Hetrick, William P.; Hong, L. Elliot; Rosen, Laura B. (June 2023). "The D-amino acid oxidase inhibitor luvadaxistat improves mismatch negativity in patients with schizophrenia in a randomized trial". Neuropsychopharmacology. 48 (7): 1052–1059. doi:10.1038/s41386-023-01560-0. ISSN 1740-634X. PMC 10018616. PMID 36928351.
  2. Wang, Hao; Norton, Jonathan; Xu, Lin; DeMartinis, Nicholas; Sen, Rohini; Shah, Ankit; Farmer, Jennifer; Lynch, David (June 2021). "Results of a randomized double‐blind study evaluating luvadaxistat in adults with Friedreich ataxia". Annals of Clinical and Translational Neurology. 8 (6): 1343–1352. doi:10.1002/acn3.51373. PMC 8164851. PMID 34018342.
  3. Fradley, Rosa; Goetghebeur, Pascal; Miller, David; Burley, Russell; Almond, Sarah; Gruart i Massó, Agnès; Delgado García, José M.; Zhu, Bin; Howley, Eimear; Neill, Jo C.; Grayson, Ben; Gaskin, Philip; Carlton, Mark; Gray, Ian; Serrats, Jordi; Davies, Ceri H. (October 2023). "Luvadaxistat: A Novel Potent and Selective d-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia". Neurochemical Research. 48 (10): 3027–3041. doi:10.1007/s11064-023-03956-2. PMC 10471729. PMID 37289348.
  4. Veselinović, Tanja; Neuner, Irene (August 2022). "Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia". CNS Drugs. 36 (8): 819–858. doi:10.1007/s40263-022-00935-z. PMC 9345797. PMID 35831706.
  5. Kuo, Chien-Yi; Lin, Chieh-Hsin; Lane, Hsien-Yuan (November 2022). "Targeting d-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research". CNS Drugs. 36 (11): 1143–1153. doi:10.1007/s40263-022-00959-5. PMID 36194364. S2CID 252694226.
  6. "Luvadaxistat". AdisInsight. 18 September 2024. Retrieved 4 November 2024.
Stub icon

This psychoactive drug-related article is a stub. You can help Misplaced Pages by expanding it.

Categories:
Luvadaxistat Add topic